1 / 19

Corporate Presentation

Corporate Presentation. INDOCO REMEDIES LTD. Indian Company with an International presence Turnover 09-10; Rs. 402.36 Crores Among the fastest growing Indian Companies Ranked 22nd in ORG IMS Rx Audit on MAT basis (ORG July 2010) Complete solution provider CRAMS – R&D, Regulatory & Mfg

raanan
Télécharger la présentation

Corporate Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Corporate Presentation INDOCO REMEDIES LTD

  2. Indian Company with an International presence Turnover 09-10; Rs. 402.36 Crores Among the fastest growing Indian Companies Ranked 22nd in ORG IMS Rx Audit on MAT basis (ORG July 2010) Complete solution provider CRAMS – R&D, Regulatory & Mfg USFDA & MCC SA approved sterile eye drops facility UK MHRA, German Darmstad, ANVISA Brazil, MCC SA approved tablets, creams & capsules facility R&D and Regulatory capabilities Employs 3000 people 100 R&D scientists 1700 field staff About Us

  3. Our Infrastructure • Corporate Office • Manufacturing Facilities • 5 Formulations facilities • 2 API facilities • R&D Centre • Depots & Branches • 34 Branches • Domestic Marketing Network • 7 divisions • PAN INDIA presence

  4. Our Business • Indian Business • Branded Generic Formulations • APIs • International Business • Regulated Markets • Generics • CRAMS • APIs • Emerging Markets • Branded Generic Formulations • APIs

  5. Indian Business • INDOCO – GP, CP, Gynaec, Life Style • SPADE – GP, CP, Paediatrician • WARREN –Dental, ENT • EXCEL – Opthal, ENT • SPERA – GP, Gynaec, Paediatrician • XTEND – GPs in Extra Urban Towns • ETERNA – CPs, Orthos, Gastro

  6. International Presence-FY10

  7. FormulationsInfrastructure

  8. API Infrastructure • KILO PLANT • Reaction Systems: 16 to 500 L • Total Reactor Volume: 1 cubic meters • Temperatures range: -55 to + 150 celsius • MULTI-TON PLANT • Reactor Capacity: 500 to 4000 L • Total Reactor Volume: 55 cubic meters • NEW OPHTHALMIC FACILITY • Reactor Capacity: 500 to 2000 L • Total reactor Volume: 15 cubic meters • INTERMEDIATES FACILITY • Reactor Capacity: 500 to 4000 L • Total Reactor Volume: 50 cubic meters

  9. R & D • The state-of-art, stand alone, US $ 8 million R & D center for Formulations, API & Intermediates is located at Rabale- near New Mumbai • The R & D center in a area of 70,000 Sq.feet is designed to accommodate more than 200 scientists and technical personnel • This center is equipped with all required sophisticated hardware and software • The state of art cGMP standard KILO LAB is a part of this Research Center

  10. R & D

  11. F & D • Over 50 Scientists working estimated to go up to 75 next year. • Launched 12 new products during last year • Completed 20 and currently working on 19 euro dossiers and completed 5 and working on 18 ANDA projects. These are Indoco’s own IP. • Filed 4 ANDAs for various US partners • 926 Formulation Dossiers of 161 products submitted to 54 countries & 20 products are under preparation for 13 countries. • Executing contracts for Development work for International Companies. Multiple site transfer projects and Euro Dossiers completed to the satisfaction of the European Customers.

  12. API ( R&D)

  13. Regulatory • 8 USDMF • 1 DMF for Canada • 4 EU DMF / COS under preparation • 5 COS • 13 APIs open part of DMF submitted to Emerging Markets

  14. Regulatory • Submitted 20 dossiers to various customers in Europe, New Zealand, Australia & SA • 19 in Pipeline • 5 ANDAs submitted • 3 ANDAs under preparation • 14 ANDAs in pipeline

  15. CRAMS

  16. Performance Highlights • Integrated player • R&D, Manufacturing & Marketing in both API & Formulations • Strong presence in India • Ranked 22nd in Rx Audit (IMS ORG) • Ranked 31st in Retail Audit (IMS ORG) • Focussed on exports • International Sales estimated to grow more than 40% • Partnering

  17. Growth Drivers • Present domestic marketing set up • Focus on high value products such as anti infective, GI products, etc. • Intensive Pan – India coverage of medical fraternity through various marketing divisions. • Partnering with Watson and Aspen • Strong R&D Set up • New Plants at Goa and Waluj

  18. Discussion Session

  19. Thank you very much

More Related